Ruxolitinib FDA Approval Status
Ruxolitinib is a JAK1/JAK2 inhibitor formulated for topical application in development for the treatment of atopic dermatitis and vitiligo.
Development Timeline for ruxolitinib
|Feb 19, 2021||Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.